CN102038651A - Ropivacaine mesylate freeze-dried powder injection - Google Patents
Ropivacaine mesylate freeze-dried powder injection Download PDFInfo
- Publication number
- CN102038651A CN102038651A CN 201010604883 CN201010604883A CN102038651A CN 102038651 A CN102038651 A CN 102038651A CN 201010604883 CN201010604883 CN 201010604883 CN 201010604883 A CN201010604883 A CN 201010604883A CN 102038651 A CN102038651 A CN 102038651A
- Authority
- CN
- China
- Prior art keywords
- ropivacaine mesylate
- freeze
- ropivacaine
- stage
- keeps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a ropivacaine mesylate freeze-dried powder injection which consists of ropivacaine mesylate and a pH regulator and is prepared by using the following freeze drying method: (1) a section quick-freezing stage: keeping bulked ropivacaine mesylate solution at the temperature of 0 DEG C for 10-30 minutes, and then keeping the bulked ropivacaine mesylate solution at the temperature of minus 35 DEG C-minus 45 DEG C for 1-2 hours; (2) a lyophilization stage: heating to 0 DEG C under the vacuum degree of 10-20 Pa and at the speed of 2-10 DEG C/h, and then keeping the temperature for 1-3 hours; and (3) a desorption drying stage: heating to 30 DEG C under the vacuum degree of 0-10 Pa and at the speed of 5-10 DEG C/h and keeping the temperature for 2-5 hours. The freeze-dried powder injection provided by the invention has the advantages of high yield, good re-dissolubility, more stable quality and the like.
Description
Technical field
The invention belongs to the Western medicine preparation technical field, be specifically related to a kind of s-ropivacaine mesylate lyophilized injectable powder.
Background technology
S-ropivacaine mesylate is the homemade novel local anesthetics of amide derivatives after the salt acid group with Ropivacaine HCL changes methanesulfonate into, cardiac toxicity is low, the sensation retardance separates more obvious with the motion retardance, the vasoconstriction effect is arranged, and therefore need not add epinephrine in use.Because it has only blocked pain nerve in use, does not influence nervus motorius, hardly by Placenta Hominis, so have the following advantages: (1) can be the puerpera effective analgesia is provided simultaneously; (2) guarantee the nervus motorius effect of bringing into normal play, do not influence uterine contraction, increase puerpera's muscle power; (3) do not influence baby's suckling and mother's postpartum recovery; (4) hypotoxicity has improved the unify safety of heart of central nervous system.Its role in clinical in childbirth and postoperative Epidural analgesia is identified and generally acknowledges.
CN101658490A discloses a kind of preparation technology of s-ropivacaine mesylate injection.Because the injection of conventional ampoule packing is operated dangerous aspect clinical use, and long-time medicinal liquid contacts with packaging material, there are hidden danger of quality such as flake, when ampoule break-off, easily produce in addition vitroclastic (outer wall of vitroclastic as without disinfection), if fall into the hidden danger that has the microbiological contamination aspect in the medicinal liquid.Also roll aluminum cap packaging outward and select for use cillin bottle to add plug, though can avoid above-mentioned hidden danger, the quality quality of plug and cleaning clean level can directly have influence on the quality of medicinal liquid.Final pressure sterilizing of palpus and medicinal liquid soaked with plug for a long time and contact during injection was produced, and plug surface silicone oil and some compositions are very easily sneaked in the medicinal liquid, influence product quality and clinical drug safety.
In following patent literature, related to the preparation method of s-ropivacaine mesylate raw material and officinal salt and lyophilized injectable powder: CN100571685C, CN 1626081A, CN 1517337A, CN 1903187A.Wherein, CN100571685C discloses a kind of preparation technology of s-ropivacaine mesylate lyophilized injectable powder, yet in the disclosed technology of the document, freeze-drying time is relatively long, production cost is higher, and used a certain amount of excipient (as mannitol) in its prescription, when clinical lumbar vertebra epidural space is injected, had certain security risk.A kind of ropivacaine lyophilized injectable powder is disclosed among the CN 1626081A, by the treatment effective dose the ropivacaine officinal salt and can constitute by cryodesiccated additives.Its preparation technology is: the water for injection that adds 40～50 ℃ in the preparation container is an amount of, adds ropivacaine and additives, stirs and makes dissolving fully, after the cooling, adds the injection water again to capacity, adds active carbon, absorption, decarbonization filtering; Gained filtrate is continued with 0.22 μ m filtering with microporous membrane, and packing, lyophilization are promptly.Though the freeze-drying time of the disclosed lyophilized injectable powder of the document is shorter, yet product appearance shape and other pharmacy indexs of preparation are unsatisfactory, yield rate is low, place the outward appearance atrophy for a long time, redissolve slowly, and there is certain security risk in its various diluent that adopt (comprising mannitol, dextran, lactose etc.) when lumbar vertebra epidural space injection use.CN 1660094A discloses a kind of ropivacaine hydrochloride in use for injection and preparation technology thereof, it adds the support substance that pharmacology allows by Ropivacaine HCL, make stay-in-grade injection powder pin or freeze-dried powder, its support substance is mannitol, lactose, glucose, dextran.Preparation method has adopted sterile cryogenic vacuum spray drying method, yet utilizes this method to prepare the s-ropivacaine mesylate injectable powder, its complicated operation, and the cost input is very high, is not suitable for industrialized great production.
In a word, in order to guarantee good lyophilizing outward appearance, the prior art of preparation ropivacaine lyophilized injectable powder has all added excipient, such as mannitol etc., thereby solves the problem that product appearance is poor, yield rate is low.Yet, the security risks (clinical safety of mannitol when excipient such as mannitol may bring lumbar vertebra epidural space drug administration by injection, little equality of summer, 2003 the 4th phases of adverse effect magazine), therefore, as the anesthetis ropivacaine of epidural injection administration,, the clinical safety of this medicine will have been increased to a great extent if in the process of preparation injectable powder, can reduce or not add any excipient.
Summary of the invention
Based on the deficiencies in the prior art, a kind of solubility and good stability, the safer s-ropivacaine mesylate lyophilized injectable powder of clinical practice have been the object of the present invention is to provide.This lyophilized injectable powder does not contain any excipient, and preparation technology is simple, lyophilization cycle short, and production cost is low, and product appearance is good after the lyophilizing, yield rate is high, and every index all meets standards of pharmacopoeia.
In order to realize purpose of the present invention, the inventor has obtained following technical scheme finally by a large amount of experimental studies:
A kind of s-ropivacaine mesylate lyophilized injectable powder is made up of s-ropivacaine mesylate and PH regulator, and adopts following freeze-drying method preparation:
(1) the segmentation quick-freezing stage: the s-ropivacaine mesylate solution that fill is good keeps 10～30min at 0 ℃, keeps 1～2h at-35 ℃～-45 ℃ then;
(2) the sublimation drying stage: at vacuum 10～20Pa, temperature keeps 1～3h after being warming up to 0 ℃ with 2～10 ℃/h;
(3) the parsing-desiccation stage: at 0～10Pa, temperature is warming up to 30 ℃ with 5～10 ℃/h in vacuum, and keeps 2～5h.
Above-mentioned s-ropivacaine mesylate lyophilized injectable powder, wherein said PH regulator are sodium hydroxide or/and phosphoric acid, and regulates described s-ropivacaine mesylate solution to PH 4～7.
Preferably, above-mentioned s-ropivacaine mesylate lyophilized injectable powder, described freeze-drying method is:
(1) the segmentation quick-freezing stage: after the s-ropivacaine mesylate solution that fill is good is put into freeze dryer, freeze dryer flaggy temperature is reduced to 0 ℃ earlier and keep 10～30min, reduce to-35 ℃～-45 ℃ again and keep 1～2h;
(2) the sublimation drying stage: vacuum is at 10～20Pa in the control freeze drying box, and the flaggy temperature is warming up to 0 ℃ with 2～10 ℃/h of constant rate of speed, and keeps 1～3h.
(3) the parsing-desiccation stage: vacuum is at 0～10Pa in the control freeze drying box, and the flaggy temperature is warming up to 30 ℃ with 5～10 ℃/h of constant rate of speed, and keeps 2～5h.
Above-mentioned any one s-ropivacaine mesylate lyophilized injectable powder, the heating rate in described sublimation drying stage is preferably 5 ℃/h.
Compared with prior art, s-ropivacaine mesylate lyophilized injectable powder of the present invention has following beneficial technical effects:
When (1) s-ropivacaine mesylate lyophilized injectable powder of the present invention does not contain any excipient, guaranteed good lyophilizing outward appearance, the security risks when having avoided lumbar vertebra epidural space drug administration by injection, clinical practice is safer.
(2) s-ropivacaine mesylate lyophilized injectable powder of the present invention adopts sectional pre-freeze mode, make that the product rate of temperature fall is faster, less and the homogeneous of crystallization particle diameter that forms, outward appearance is loose evenly after the lyophilizing, solubility is better, the security risks when having overcome prior art and be the lumbar vertebra epidural space drug administration by injection that a large amount of excipient that the good lyophilizing outward appearance of assurance is added bring.
(3) investigate result of the test as can be known by outward appearance, solubility, content and the related substance of the s-ropivacaine mesylate lyophilized injectable powder of embodiment 5, compared with prior art, s-ropivacaine mesylate lyophilized injectable powder of the present invention has the yield rate height, solubility is good, advantages such as more stable quality, whole freeze-dry process is consuming time shorter, has shortened production cost greatly, has alleviated patient economy burden.
The specific embodiment
Below be specific embodiments of the invention, technical scheme of the present invention is further described, but protection scope of the present invention is not limited to these embodiment.Every do not deviate from the change of the present invention design or be equal to substitute include within protection scope of the present invention.
Embodiment 1The preparation of s-ropivacaine mesylate lyophilized injectable powder
Prescription: s-ropivacaine mesylate 89.4g
Water for injection adds to 1000mL
Make 1000
Preparation: take by weighing s-ropivacaine mesylate 89.4g, add 80% recipe quantity and be chilled to the water for injection of room temperature, stirring makes dissolving fully, sodium hydroxide or phosphoric acid are regulated medicinal liquid PH to 4～7, add 0.5 ‰ needle-use activated carbon, stirring and adsorbing 10 minutes, back decarburization is filtered, add water for injection to 1000mL, stir.After 0.22 μ m degerming filter membrane twin-stage aseptic filtration, the filtrate sampling detects semi-finished product content, and according to the medicinal liquid of content fill standard quantity in the cillin bottle of cleaning, the false add plug is put into the freeze dryer lyophilization.Freeze drying process is as follows, and lyophilizing finishes, aluminium lid is rolled in the vacuum tamponade outward, visual inspection, packs.
Freeze drying process:
1) the pre-freeze stage: after the s-ropivacaine mesylate semi-finished product are put into freeze dryer, earlier freeze dryer flaggy temperature is reduced to 0 ℃ with rapid rate, kept 30 minutes, reduce to-45 ℃ with rapid rate again, kept 1.5 hours.
2) the sublimation drying stage: vacuum 10～20Pa in the control freeze drying box, the flaggy temperature is warming up to 0 ℃ for 5 ℃/hour with constant rate of speed, and keeps 2 hours.
3) the parsing-desiccation stage: vacuum 0～10Pa in the control freeze drying box, the flaggy temperature is warming up to 30 ℃ for 10 ℃/hour with constant rate of speed, and keeps 3 hours, promptly gets s-ropivacaine mesylate powder pin.
Embodiment 2The preparation of s-ropivacaine mesylate lyophilized injectable powder
Prescription: s-ropivacaine mesylate 47.7g
Water for injection adds to 1000mL
Make 1000
Preparation: take by weighing s-ropivacaine mesylate 47.7g, add 80% recipe quantity and be chilled to the water for injection of room temperature, stirring makes dissolving fully, sodium hydroxide or phosphoric acid are regulated medicinal liquid PH to 4～7, add 1 ‰ needle-use activated carbon, stirring and adsorbing 10 minutes, back decarburization is filtered, add water for injection to 1000mL, stir.After 0.22 μ m degerming filter membrane twin-stage aseptic filtration, the filtrate sampling detects semi-finished product content, and according to the medicinal liquid of content fill standard quantity in the cillin bottle of cleaning, the false add plug is put into the freeze dryer lyophilization.Freeze drying process is as follows, and lyophilizing finishes, aluminium lid is rolled in the vacuum tamponade outward, visual inspection, packs.
Freeze drying process:
1) the pre-freeze stage: after the s-ropivacaine mesylate semi-finished product are put into freeze dryer, earlier freeze dryer flaggy temperature is reduced to 0 ℃ with rapid rate, kept 20 minutes, reduce to-40 ℃ with rapid rate again, kept 2 hours.
2) the sublimation drying stage: vacuum 10～15Pa in the control freeze drying box, the flaggy temperature is warming up to 0 ℃ for 10 ℃/hour with constant rate of speed, and keeps 2 hours.
3) the parsing-desiccation stage: vacuum 0～10Pa in the control freeze drying box, the flaggy temperature is warming up to 30 ℃ for 10 ℃/hour with constant rate of speed, and keeps 5 hours, promptly gets s-ropivacaine mesylate powder pin.
Embodiment 3The preparation of s-ropivacaine mesylate lyophilized injectable powder
Prescription: s-ropivacaine mesylate 89.4g
Water for injection adds to 500mL
Make 1000
Preparation: take by weighing s-ropivacaine mesylate 89.4g, add 80% recipe quantity and be chilled to the water for injection of room temperature, stirring makes dissolving fully, sodium hydroxide or phosphoric acid are regulated medicinal liquid PH to 4～7, add 1 ‰ needle-use activated carbon, stirring and adsorbing 10 minutes, back decarburization is filtered, add water for injection to 500mL, stir.After 0.22 μ m degerming filter membrane twin-stage aseptic filtration, the filtrate sampling detects semi-finished product content, and according to the medicinal liquid of content fill standard quantity in the cillin bottle of cleaning, the false add plug is put into the freeze dryer lyophilization.Freeze drying process is as follows, and lyophilizing finishes, aluminium lid is rolled in the vacuum tamponade outward, visual inspection, packs.
Freeze drying process:
1) the pre-freeze stage: after the s-ropivacaine mesylate semi-finished product are put into freeze dryer, earlier freeze dryer flaggy temperature is reduced to 0 ℃ with rapid rate, kept 10 minutes, reduce to-35 ℃ with rapid rate again, kept 1 hour.
2) the sublimation drying stage: vacuum 10～20Pa in the control freeze drying box, the flaggy temperature is warming up to 0 ℃ for 10 ℃/hour with constant rate of speed, and keeps 1 hour.
3) the parsing-desiccation stage: vacuum 0～10Pa in the control freeze drying box, the flaggy temperature is warming up to 30 ℃ for 5 ℃/hour with constant rate of speed, and keeps 2 hours, promptly gets s-ropivacaine mesylate powder pin.
Embodiment 4The preparation of s-ropivacaine mesylate lyophilized injectable powder
Prescription: s-ropivacaine mesylate 47.7g
Water for injection adds to 500mL
Make 1000
Preparation: take by weighing s-ropivacaine mesylate 47.7g, add 80% recipe quantity and be chilled to the water for injection of room temperature, stirring makes dissolving fully, sodium hydroxide or phosphoric acid are regulated medicinal liquid PH to 4～7, add 0.5 ‰ needle-use activated carbon, stirring and adsorbing 10 minutes, back decarburization is filtered, add water for injection to 500mL, stir.After 0.22 μ m degerming filter membrane twin-stage aseptic filtration, the filtrate sampling detects semi-finished product content, and according to the medicinal liquid of content fill standard quantity in the cillin bottle of cleaning, the false add plug is put into the freeze dryer lyophilization.Freeze drying process is as follows, and lyophilizing finishes, aluminium lid is rolled in the vacuum tamponade outward, visual inspection, packs.
Freeze drying process:
1) the pre-freeze stage: after the s-ropivacaine mesylate semi-finished product are put into freeze dryer, earlier freeze dryer flaggy temperature is reduced to 0 ℃ with rapid rate, kept 15 minutes, reduce to-40 ℃ with rapid rate again, kept 1 hour.
2) the sublimation drying stage: vacuum 10～20Pa in the control freeze drying box, the flaggy temperature is warming up to 0 ℃ for 8 ℃/hour with constant rate of speed, and keeps 1 hour.
3) the parsing-desiccation stage: vacuum 0～10Pa in the control freeze drying box, the flaggy temperature is warming up to 30 ℃ for 8 ℃/hour with constant rate of speed, and keeps 3 hours, promptly gets s-ropivacaine mesylate powder pin.
The outward appearance of embodiment 5 s-ropivacaine mesylate lyophilized injectable powders of the present invention, solubility, content and related substance are investigated test
Investigate group: the preparation method according to the embodiment of the invention 1 prepares the s-ropivacaine mesylate lyophilized injectable powder
Adopt the s-ropivacaine mesylate lyophilized injectable powder of embodiment 1 preparation among the CN100571685C
Adopt the s-ropivacaine mesylate lyophilized injectable powder of embodiment 1 preparation among the CN1626081A
Investigate index: the outward appearance of product, solubility, content and related substance
The investigation method:
Content, related substance detection method are Same Way, all adopt high performance liquid chromatography (according to two appendix VD of Chinese Pharmacopoeia version in 2010) to measure.
Chromatographic condition: with octadecylsilane chemically bonded silica is filler.With acetonitrile-phosphate buffer (get the sodium dihydrogen phosphate 1.3ml of 1mol/L, 0.05mol/L disodium phosphate soln 32.5ml adds water to 1000ml, is adjusted to pH8.0) is mobile phase (600:400); Wavelength is 240nm, and theoretical cam curve is calculated by the s-ropivacaine mesylate peak and is not less than 2000.
Algoscopy: get the content under the content uniformity item, mix homogeneously, precision takes by weighing this product an amount of (being equivalent to s-ropivacaine mesylate 50mg approximately), put in the volumetric flask of 50ml, with water dissolution and be diluted to scale, shake up, precision takes by weighing 20ul and injects chromatograph of liquid, the record chromatogram; It is an amount of that other gets the s-ropivacaine mesylate reference substance, and accurate the title decides, and makes the solution that contains s-ropivacaine mesylate 0.24mg among every 1ml with water dissolution and dilution, measures with method.Press external standard method with calculated by peak area, promptly.
Other index detects all and requires to measure according to Chinese Pharmacopoeia version appendix in 2010.
It is as follows referring to table 1 to investigate the result:
The table 1 product number of rejects and percent defective (with every batch of 1000 bottles of calculating)
| Defective reason | Atrophy | Layering | Caking | Percent defective |
| The embodiment of the invention 1 | 2 | 0 | 2 | 0.4% |
| CN100571685C embodiment 1 | 3 | 3 | 4 | 1.0% |
| CN1626081A embodiment 1 | 68 | 21 | 15 | 10.4% |
Get each 10 of the injectable powder of each group preparation, add 5ml particulate matter inspection water dissolution, check product solubility, redissolve after the clarity and the visible foreign matters of medicinal liquid, the result participates in table 2
The result is investigated in the contrast of table 2 product solubility
| ? | Redissolution speed | Clarity | Visible foreign matters |
| The embodiment of the invention 1 | Comparatively fast, dissolving fully in 40 seconds | All colourless, the clarification of solution | All qualified |
| CN100571685C embodiment 1 | Hurry up dissolving fully in 1 minute | All colourless, the clarification of solution | All qualified |
| CN1626081A embodiment 1 | Hurry up dissolving fully in 75 seconds | All colourless, the clarification of solution | 9 qualified, 1 defective |
Get the semi-finished product medicinal liquid of each assembly system, under room temperature, together place and investigate stability, detect every index behind the 8h, the results are shown in Table 3.
Get that lyophilized injectable powder of each group preparation is an amount of to detect related item with putting under 40 ℃, RH75% constant temperature and humidity condition respectively at sampling in 0,3,6,12 month, the results are shown in Table 4.
Claims (4)
1. s-ropivacaine mesylate lyophilized injectable powder, it is characterized in that: it is made up of s-ropivacaine mesylate and PH regulator, and adopts following freeze-drying method preparation:
(1) the segmentation quick-freezing stage: the s-ropivacaine mesylate solution that fill is good keeps 10～30min at 0 ℃, keeps 1～2h at-35 ℃～-45 ℃ then;
(2) the sublimation drying stage: at vacuum 10～20Pa, temperature keeps 1～3h after being warming up to 0 ℃ with 2～10 ℃/h;
(3) the parsing-desiccation stage: at 0～10Pa, temperature is warming up to 30 ℃ with 5～10 ℃/h in vacuum, and keeps 2～5h.
2. s-ropivacaine mesylate lyophilized injectable powder as claimed in claim 1 is characterized in that: described PH regulator is a sodium hydroxide or/and phosphoric acid, and regulates described s-ropivacaine mesylate solution to PH 4～7.
3. s-ropivacaine mesylate lyophilized injectable powder as claimed in claim 1 is characterized in that: described freeze-drying method is:
(1) the segmentation quick-freezing stage: after the s-ropivacaine mesylate solution that fill is good is put into freeze dryer, freeze dryer flaggy temperature is reduced to 0 ℃ earlier and keep 10～30min, reduce to-35 ℃～-45 ℃ again and keep 1～2h;
(2) the sublimation drying stage: vacuum is at 10～20Pa in the control freeze drying box, and the flaggy temperature is warming up to 0 ℃ with 2～10 ℃/h of constant rate of speed, and keeps 1～3h;
(3) the parsing-desiccation stage: vacuum is at 0～10Pa in the control freeze drying box, and the flaggy temperature is warming up to 30 ℃ with 5～10 ℃/h of constant rate of speed, and keeps 2～5h.
4. as claim 1 or 3 described s-ropivacaine mesylate lyophilized injectable powders, it is characterized in that: the heating rate in described sublimation drying stage is 5 ℃/h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010604883 CN102038651B (en) | 2010-12-25 | 2010-12-25 | Ropivacaine mesylate freeze-dried powder injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010604883 CN102038651B (en) | 2010-12-25 | 2010-12-25 | Ropivacaine mesylate freeze-dried powder injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102038651A true CN102038651A (en) | 2011-05-04 |
| CN102038651B CN102038651B (en) | 2013-04-03 |
Family
ID=43905420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010604883 Active CN102038651B (en) | 2010-12-25 | 2010-12-25 | Ropivacaine mesylate freeze-dried powder injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102038651B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705473A (en) * | 2013-12-26 | 2014-04-09 | 山东博迈康药物研究有限公司 | Lansoprazole freeze-dried powder injection and preparation method thereof |
| CN105125486A (en) * | 2015-10-15 | 2015-12-09 | 扬子江药业集团南京海陵药业有限公司 | Preparation method for ropivacaine mesylate injection solution |
| CN106109423A (en) * | 2016-07-13 | 2016-11-16 | 山西普德药业有限公司 | A kind of injection Vistamycin lyophilized injectable powder and preparation method thereof |
| US10821087B2 (en) | 2015-07-24 | 2020-11-03 | Neon Laboratories Limited | Stabilized injectable emulsion of Propofol and Ketamine |
| CN112460924A (en) * | 2020-10-16 | 2021-03-09 | 河北常山生化药业股份有限公司 | Freeze-drying process of exenatide precursor |
| US11224593B2 (en) | 2015-07-13 | 2022-01-18 | Neon Laboratories Limited | Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1626081A (en) * | 2003-12-10 | 2005-06-15 | 北京博尔达生物技术开发有限公司 | Ropivacaine freeze-dried powder and injection preparation in use for injection and preparation method |
| CN1660094A (en) * | 2004-12-13 | 2005-08-31 | 黄健鹏 | Ropivacaine hydrochloride in use for injection and preparation technique |
| CN100998567A (en) * | 2007-01-05 | 2007-07-18 | 山东鲁抗辰欣药业有限公司 | Ropivacaine, and its pharmaceutical salt freeze-dried powder-injection preparation and art for preparing the same |
| CN101125126A (en) * | 2006-08-16 | 2008-02-20 | 丛繁滋 | Method for preparing medical freeze-dried powder (injection) preparation |
| CN101596168A (en) * | 2009-07-10 | 2009-12-09 | 曾因明 | Lumbar anesthesia dedicated offices anaesthetic-glucose lyophilized powder injection and preparation method and packing method thereof |
-
2010
- 2010-12-25 CN CN 201010604883 patent/CN102038651B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1626081A (en) * | 2003-12-10 | 2005-06-15 | 北京博尔达生物技术开发有限公司 | Ropivacaine freeze-dried powder and injection preparation in use for injection and preparation method |
| CN1660094A (en) * | 2004-12-13 | 2005-08-31 | 黄健鹏 | Ropivacaine hydrochloride in use for injection and preparation technique |
| CN101125126A (en) * | 2006-08-16 | 2008-02-20 | 丛繁滋 | Method for preparing medical freeze-dried powder (injection) preparation |
| CN100998567A (en) * | 2007-01-05 | 2007-07-18 | 山东鲁抗辰欣药业有限公司 | Ropivacaine, and its pharmaceutical salt freeze-dried powder-injection preparation and art for preparing the same |
| CN101596168A (en) * | 2009-07-10 | 2009-12-09 | 曾因明 | Lumbar anesthesia dedicated offices anaesthetic-glucose lyophilized powder injection and preparation method and packing method thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705473A (en) * | 2013-12-26 | 2014-04-09 | 山东博迈康药物研究有限公司 | Lansoprazole freeze-dried powder injection and preparation method thereof |
| CN103705473B (en) * | 2013-12-26 | 2016-02-10 | 山东博迈康药物研究有限公司 | A kind of Lansoprazole freeze-dried injection and preparation method thereof |
| US11224593B2 (en) | 2015-07-13 | 2022-01-18 | Neon Laboratories Limited | Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof |
| US10821087B2 (en) | 2015-07-24 | 2020-11-03 | Neon Laboratories Limited | Stabilized injectable emulsion of Propofol and Ketamine |
| CN105125486A (en) * | 2015-10-15 | 2015-12-09 | 扬子江药业集团南京海陵药业有限公司 | Preparation method for ropivacaine mesylate injection solution |
| CN106109423A (en) * | 2016-07-13 | 2016-11-16 | 山西普德药业有限公司 | A kind of injection Vistamycin lyophilized injectable powder and preparation method thereof |
| CN112460924A (en) * | 2020-10-16 | 2021-03-09 | 河北常山生化药业股份有限公司 | Freeze-drying process of exenatide precursor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102038651B (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038651B (en) | Ropivacaine mesylate freeze-dried powder injection | |
| CN102274195B (en) | Oxiracetam freeze-dried powder preparation and preparation method thereof | |
| CN105434373A (en) | Oxiracetam freeze-drying preparation for injection and preparation method thereof | |
| CN102512378A (en) | Stable and safe oxiracetam pharmaceutical composition for injection | |
| CN101756915B (en) | Tirofiban hydrochloride lyophilized powder injection and preparation method thereof | |
| CN102657622A (en) | Preparation process of freeze-dry powder injection containing esomeprazole sodium | |
| CN102276533B (en) | New ozagrel sodium compound and medicinal composition thereof | |
| CN102784382A (en) | Argatroban drug composition and preparation method and application of argatroban drug composition | |
| CN100571685C (en) | The preparation technology of a kind of ropivacaine and officinal salt lyophilized injectable powder thereof | |
| CN102038680B (en) | Medical composition | |
| CN102743342B (en) | Sodium fusidate lyophilized composition for injection | |
| CN103494779B (en) | Andrographolide powder preparation for injection and preparation method thereof | |
| CN101904862A (en) | Water-soluble vitamin composition freeze-drying preparation for injection | |
| CN103142507A (en) | Clindamycin phosphate preparation for injection and preparation method thereof | |
| CN113476412A (en) | Preparation method of piracetam freeze-dried powder injection for injection | |
| CN103432086B (en) | Pemetrexed disodium freeze-dried powder injection for injection and preparation method thereof | |
| CN103040765B (en) | Pharmaceutical composition containing adenosine disodium triphosphate and preparation method of pharmaceutical composition | |
| CN102813631B (en) | Method for preparing phentolamine mesilate freeze-drying powder injection | |
| CN107432860B (en) | Preparation method of levo-oxiracetam freeze-dried powder | |
| CN103877013A (en) | Asarin injection and preparation method thereof | |
| CN107397722B (en) | (S) -4-hydroxy-2-oxo-1-pyrrolidine acetamide freeze-dried powder for injection and preparation method thereof | |
| CN107432861B (en) | Levo-oxiracetam freeze-dried composition for injection and preparation method thereof | |
| CN102526042B (en) | Stable liquid medicinal composition | |
| CN103330932B (en) | The pharmaceutical composition of a kind of MFG or its salt | |
| CN102133198B (en) | Ifenprodil tartrate freeze-dried powder injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221123 Address after: 273400 Shandong city of Linyi province Feixian County North Ring Road No. 1 Patentee after: LUNAN NEW TIME BIO-TECH Co.,Ltd. Address before: 273400 Shandong city of Linyi province Feixian County North Ring Road No. 1 Patentee before: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |